These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 30185782)

  • 1. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma.
    Mukherjee N; Strosnider A; Vagher B; Lambert KA; Slaven S; Robinson WA; Amato CM; Couts KL; Bemis JGT; Turner JA; Norris DA; Shellman YG
    Cell Death Dis; 2018 Sep; 9(9):907. PubMed ID: 30185782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
    Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
    Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
    Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.
    Mukherjee N; Lu Y; Almeida A; Lambert K; Shiau CW; Su JC; Luo Y; Fujita M; Robinson WA; Robinson SE; Norris DA; Shellman YG
    Oncotarget; 2017 Jul; 8(29):46801-46817. PubMed ID: 27086916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis.
    Milani M; Byrne DP; Greaves G; Butterworth M; Cohen GM; Eyers PA; Varadarajan S
    Cell Death Dis; 2017 Jan; 8(1):e2552. PubMed ID: 28079887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
    Modi V; Sankararamakrishnan R
    J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.
    Mukherjee N; Almeida A; Partyka KA; Lu Y; Schwan JV; Lambert K; Rogers M; Robinson WA; Robinson SE; Applegate AJ; Amato CM; Luo Y; Fujita M; Norris DA; Shellman YG
    Oncotarget; 2016 Dec; 7(51):84594-84607. PubMed ID: 27829238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
    J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
    Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
    Zhang L; Ramesh P; Steinmetz M; Medema JP
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
    Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
    Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
    Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization and validation of mitochondria-based functional assay as a useful tool to identify BH3-like molecules selectively targeting anti-apoptotic Bcl-2 proteins.
    Long J; Liu L; Nikolovska-Coleska Z; Shangary S; Yi H; Wang S; Wang S
    BMC Biotechnol; 2013 May; 13():45. PubMed ID: 23705845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
    Jullien M; Gomez-Bougie P; Chiron D; Touzeau C
    Cells; 2020 Mar; 9(3):. PubMed ID: 32183335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells.
    Vera MB; Morris-Hanon O; Nogueiras GI; Ripari LB; Esquivel MI; Perez-Castro C; Romorini L; Sevlever GE; Scassa ME; Videla-Richardson GA
    Sci Rep; 2022 Oct; 12(1):17729. PubMed ID: 36273072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes.
    Pemberton JM; Nguyen D; Osterlund EJ; Schormann W; Pogmore JP; Hirmiz N; Leber B; Andrews DW
    Elife; 2023 Apr; 12():. PubMed ID: 37078707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA.
    Keuling AM; Andrew SE; Tron VA
    Pigment Cell Melanoma Res; 2010 Jun; 23(3):430-40. PubMed ID: 20337986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
    Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
    Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mito-priming as a method to engineer Bcl-2 addiction.
    Lopez J; Bessou M; Riley JS; Giampazolias E; Todt F; Rochegüe T; Oberst A; Green DR; Edlich F; Ichim G; Tait SW
    Nat Commun; 2016 Feb; 7():10538. PubMed ID: 26833356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.